Weekly Analysts’ Ratings Updates for Johnson & Johnson (JNJ)

A number of firms have modified their ratings and price targets on shares of Johnson & Johnson (NYSE: JNJ) recently:

• 2/3/2025 – Johnson & Johnson had its price target raised by analysts at Guggenheim from $162.00 to $166.00. They now have a “neutral” rating on the stock.
• 1/28/2025 – Johnson & Johnson had its price target raised by analysts at Barclays PLC from $159.00 to $166.00. They now have an “equal weight” rating on the stock.
• 1/25/2025 – Johnson & Johnson was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 1/24/2025 – Johnson & Johnson was upgraded by analysts at Argus to a “strong-buy” rating.
• 1/23/2025 – Johnson & Johnson had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $181.00 price target on the stock.
• 1/23/2025 – Johnson & Johnson had its price target lowered by analysts at Leerink Partners from $182.00 to $169.00. They now have an “outperform” rating on the stock.
• 1/23/2025 – Johnson & Johnson had its price target lowered by analysts at Raymond James from $170.00 to $165.00. They now have an “outperform” rating on the stock.
• 1/23/2025 – Johnson & Johnson had its price target lowered by analysts at Bank of America Co. from $160.00 to $159.00. They now have a “neutral” rating on the stock.
• 1/23/2025 – Johnson & Johnson had its price target lowered by analysts at Stifel Nicolaus from $170.00 to $155.00. They now have a “hold” rating on the stock.
• 1/23/2025 – Johnson & Johnson had its price target lowered by analysts at Morgan Stanley from $175.00 to $163.00. They now have an “equal weight” rating on the stock.
• 1/23/2025 – Johnson & Johnson had its price target lowered by analysts at Wells Fargo & Company from $166.00 to $152.00. They now have an “equal weight” rating on the stock.
• 1/21/2025 – Johnson & Johnson had its price target lowered by analysts at Barclays PLC from $160.00 to $159.00. They now have an “equal weight” rating on the stock.
• 1/17/2025 – Johnson & Johnson had its price target lowered by analysts at Bank of America Co. from $166.00 to $160.00. They now have a “neutral” rating on the stock.
• 1/17/2025 – Johnson & Johnson was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 1/7/2025 – Johnson & Johnson was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 12/11/2024 – Johnson & Johnson had its price target lowered by analysts at Citigroup Inc. from $185.00 to $175.00. They now have a “buy” rating on the stock.
• 12/10/2024 – Johnson & Johnson had its “neutral” rating reaffirmed by analysts at Bank of America Co.. They now have a $166.00 price target on the stock.

Johnson & Johnson Trading Up 0.9 %

Shares of Johnson & Johnson stock traded up $1.30 during trading hours on Tuesday, reaching $153.17. The stock had a trading volume of 3,024,541 shares, compared to its average volume of 9,182,655. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The firm has a market capitalization of $368.78 billion, a price-to-earnings ratio of 23.03, a P/E/G ratio of 2.44 and a beta of 0.52. The firm has a 50 day simple moving average of $147.53 and a two-hundred day simple moving average of $156.10.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the previous year, the company posted $2.29 earnings per share. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.24%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

Institutional investors have recently added to or reduced their stakes in the company. Powers Advisory Group LLC boosted its holdings in Johnson & Johnson by 0.6% in the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock valued at $1,538,000 after purchasing an additional 61 shares during the last quarter. Eagle Wealth Strategies LLC boosted its stake in shares of Johnson & Johnson by 2.8% during the 3rd quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company’s stock valued at $372,000 after buying an additional 63 shares during the last quarter. Knuff & Co LLC grew its position in shares of Johnson & Johnson by 0.7% during the third quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after buying an additional 64 shares in the last quarter. Perkins Coie Trust Co increased its stake in shares of Johnson & Johnson by 1.8% in the third quarter. Perkins Coie Trust Co now owns 3,705 shares of the company’s stock worth $600,000 after buying an additional 65 shares during the last quarter. Finally, Vertex Planning Partners LLC boosted its stake in Johnson & Johnson by 1.3% during the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock valued at $844,000 after acquiring an additional 65 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.